001
ABOUT FUTURE PHARMACEUTICALS
We are neither a traditional pharmaceutical laboratory nor an academic institution.
We have combined the best of both without the limitations of either:
WE ARE AN EXPERIMENTAL RESEARCH FACILITY ON A MISSION TO RADICALLY ENHANCE HUMAN PERFORMANCE WITH THE MOST ADVANCED BIOTECHNOLOGY IN HISTORY. ///////////
Future pharma was founded in silicon valley as a vehicle for exploring the very limits of human performance. With a background in organic chemistry and synthetic biology, we blur the boundaries between biology and technology to develop the next generation human enhancement biotech.
WE MAY NOT BE THE LARGEST OR MOST WELL-KNOWN, BUT WE DEVELOP SOME OF THE INDUSTRIES MOST EFFECTIVE BIOPHARMA. ///////////
WELCOME TO THE FUTURE
////////////
WELCOME TO THE FUTURE ////////////
002MISSION
Our mission is stated simply, yet it is quite ambitious: we are tackling one of the most challenging and fundamental biological mysteries of our time:
WHAT IS THE UNDERLYING CELLULAR BIOLOGY THAT DETERMINES AGING?
…and use the knowledge we gain to develop interventions that will redefine the limits of human potential.
003 
THE EXPERIMENT THAT STARTED IT ALL
Dr. Kenyon's Breakthrough at the University of California (UCSF) Doubles Lifespan, Proving Aging Can Be Biologically Hacked
Aging was once considered an inevitable process.
Cynthia Kenyon, PhD, now Vice President of Aging at Google's secret anti-aging biotech division, conducted a landmark study at the University of California, San Francisco (UCSF). Her research revealed that activation of the daf-2 molecular pathway doubled animal lifespans while enhancing their youth and vitality.
This groundbreaking work proved, for the first time, that aging and performance can be modulated at the molecular level.
Check out Cynthia’s paper in Nature titled, “A C. elegans mutant that lives twice as long as wild type.”
Geneticist Cynthia Kenyon, University of CaliforniaIMMORTALITY IS NOW THEORETICALLY POSSIBLE /////////
WHY NOW?
Because we believe the human enhancement industry has reached a barrier beyond which it cannot further extend human performance with its current technologies:
Outdated hormone-based performance-enhancing drugs (PEDs) offer short-term results at the cost of long-term side effects.
Whilst conventional nutritional supplements, while lacking side effects, also lack meaningful efficacy.
004DISRUPTING THE STATUS QUO OF THE SUPPLEMENT INDUSTRY.
Landmark scientific discoveries over the past 20 years—from decoding the human genome to identifying cellular causes of aging—have unlocked solutions that redefine the limits of human performance.
In collaboration with the world’s leading scientists, Future is creating an entirely new category in the industry by translating anti-aging breakthroughs into genomic enhancement biotechnologies.
WE BELIEVE THIS IS AN ENTIRELY NEW APPROACH
TO HUMAN ENHANCEMENT /////////
005
Medical research is the driving force behind performance-enhancing biopharma. Today’s PEDs were often accidental byproducts derived from failed attempts to create medically useful products: steroids for muscle wasting, EPO for anemia, and HGH for growth deficiencies. LSD was a central nervous stimulant, and MDMA—known as ‘ecstasy’—was originally intended to prevent bleeding.
Future Pharma operates at the intersection of medical research and enhancement requirements, where discoveries for tomorrow’s biopharma emerge. From Harvard’s anti-aging research to the U.S. military's Super Soldier program, we translate cutting-edge science into publicly available products.
HARNESSING BREAKTHROUGHS FROM WORLD-LEADING INSTITUTIONS
////////// BLEEDING EDGE OF MEDICAL RESEARCH.
-
// Das, Abhirup et al. Cell vol. 173,1 (2018)
GW501516: An experimental compound developed by pharma giant GlaxoSmithKline (GSK) and San Diego's Salk Institute, codenamed '516' and referred to as "exercise in a pill."
Targeting the PPAR molecular pathway, GW501516 mimics the effects of high-intensity exercise without the need for physical exertion. It enhances fat oxidation and muscle development, simulating the metabolic benefits experienced by elite athletes.
Preclinical trials demonstrated a remarkable 70% increase in time to exhaustion, with participants improving from 160 to 270 minutes.
-
Researchers at Harvard Medical School, led by Dr. David Sinclair, uncovered the SIRT molecular pathway—widely regarded as the elusive root cause of aging.
Their identification of compounds like NMN and MIB-626, which enhance SIRTUIN activity, has opened the door to the possibility of a true "fountain of youth."
Preclinical testing at Harvard revealed significant metabolic, musculoskeletal, and aerobic enhancements, culminating in a pioneering Wenzhou Medical University trial that demonstrated a 20% increase in median lifespan in test subjects—a discovery that has forever altered the science of human longevity.
Gu, Yanrou et al. “β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice.” Food & function vol. 15,6 3199-3213. 18 Mar. 2024, doi:10.1039/d3fo05221dere
-
Astronauts face accelerated aging due to cosmic radiation. On a mission to Mars, up to five percent of their cells would die, and the risk of cancer would approach 100 percent.
UNSW researchers have developed MIB-626—a groundbreaking drug that reverses aging, repairs DNA, and enhances physiological performance, offering a potential solution to protect astronauts on their journey to Mars.
Harvard trials revealed significant improvements in muscle function, metabolism, and energy. The most notable outcome was a 56 to 80 percent increase in exercise capacity among participants.
Das, Abhirup et al. “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging.” Cell vol. 173,1 (2018): 74-89.e20. doi:10.1016/j.cell.2018.02.00
-
// The Pentagon's DARPA (Defense Advanced Research Projects Agency), the research arm of the U.S. military, is conducting an elite soldier project, 'Metabolic Dominance,' aimed at biochemically hacking metabolism to push the limits of human endurance.
Their breakthrough discovery, D-BHB, is a new form of energy that acts as a metabolic superfuel—revolutionizing energy production by enhancing mitochondrial efficiency and optimizing oxygen utilization at the cellular level.
Phase 1 of the study, conducted in collaboration with the U.S. Special Operations Command (USSOCOM), demonstrated a 15% improvement in mean power output among athletes following the BHB protocol during endurance training sessions.
McCarthy, Devin G et al. “Increased cardiorespiratory stress during submaximal cycling after ketone monoester ingestion in endurance-trained adults.” Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme vol. 46,8 (2021): 986-993. doi:10.1139/apnm-2020-09990
006WE ARE DIFFERENT BY DESIGN
Our focus is not on marketing existing nutritional products, but on the inception of next-generation technologies that deliver lasting value to the scientific community.
With human clinical trials completed, several patents granted, and showcased in international news, Future Pharma has designed and produced some of the most effective ergogenic aids in the industry—advancing longevity, musculoskeletal health, metabolic function, aerobic capacity, and cognitive enhancement.
///////// FEATURED ACROSS INTERNATIONAL MEDIA
-
// Ebert, Scott M et al, The Journal of biological chemistry
University of Iowa scientist Christopher Adams, MD, PhD, and UI professor, identified the first known cause of age-related muscle weakness and atrophy—the transcription factor ATF4.
They also discovered two natural compounds, ursolic acid and tomatidine, that inhibit ATF4 activity in aged skeletal muscle, leading to a 10% increase in muscle mass and, more importantly, a 30% increase in muscle quality and strength—remarkable results that have drawn the attention of leading scientists worldwide.
Ebert, Scott M et al. “Identification and Small Molecule Inhibition of an Activating Transcription Factor 4 (ATF4)-dependent Pathway to Age-related Skeletal Muscle Weakness and Atrophy.” The Journal of biological chemistry vol. 290,42 (2015): 25497-511. doi:10.1074/jbc.M115.681445
HUMAN CLINICAL TRIALS
//Epicatechin (-)- Inhibits Catabolic Myostatin, Producing A 7% Strength Gain In 7 Days In A Mexican Instituto De Medicina Human Trial
FEATURED IN INTERNATIONAL PRESS
// "The Silicon Valley Startup hacking human Performance at the Molecular Level"
PATENTED SUPERIOR COMPOUNDS
// Molecularly modified HMB analog HICA, developed with Johns Hopkins University, produces 367% greater anti-catabolic effects compared to standard HMB.
007THE FIRST HUMAN CLINICALLY VALIDATED ENHANCEMENT BIOPHARMA
SCIENCE: OUR CORE VALUE
In an industry plagued by unsubstantiated claims, our commitment to rigorous research and scientific integrity sets us apart.
We are among the very first companies to conduct full clinical validation of our compounds. Our R&D process begins with preclinical research and culminates in rigorous, placebo-controlled human trials—differentiating us from mainstream supplement companies that rely on pseudoscience rather than science.
NEW MOLECULES. NEW POTENCY. ///////////
-
MOLECULE:
(+)-20-Hydroxyecdysone: A natural steroid-like molecule that mimics the effects of testosterone by targeting the mTOR molecular pathway.STUDY:
Researchers divided 46 young men into four groups. Three groups trained with weights during the 10-week trial. One group took a placebo [PL], while the other two groups used a supplement containing ecdysterone.RESULTS:
German biochemists associated with WADA (World Anti-Doping Agency) recorded 2kg of muscle growth and a 19.4% strength gain. They observed that (+)-20-Hydroxyecdysone has an anabolic effect comparable to DHT, the potent androgenic metabolite of testosterone, while exhibiting zero androgenic side effects and remaining 100% legal.RESEARCH:
Department for Molecular and Cellular Sports Medicine, German Sport University Cologne.Isenmann, Eduard et al. “Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans.”
-
//MOLECULE
Epicatechin (-)-: A naturally occurring flavonoid that inhibits the master catabolic myostatin 'OFF' molecular switch, often referred to as the 'holy grail' of muscle enhancement.While there are a few supplements known to interact with myostatin signaling (such as sulforaphane), none had been tested in the context of human supplementation—until now.
STUDY
A human study was conducted on six individuals in their forties and six in their seventies. The subjects were given two daily doses of 25 mg (-)-epicatechin for seven days. The subjects were relatively lightweight and received a total of 1 mg (-)-epicatechin per kg of body weight per day. The researchers then measured the supplement’s effects on the subjects' grip strength and the concentrations of myostatin and follistatin in their blood.
RESULTS
The study reported that treatment for seven days with (-)-epicatechin resulted in a 7% bilateral increase in hand strength, accompanied by a significant 49.2% increase in plasma follistatin levels and a 16.6% decrease in myostatin levels—key biochemical markers of muscle growth.RESEARCH
Mexican Escuela Superior de Medicina del Instituto Politécnico NacionalGutierrez-Salmean, Gabriela et al. “Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation.” The Journal of Nutritional Biochemistry vol. 25,1 (2014): 91-4. doi:10.1016/j.jnutbio.2013.09.00707
-
//MOLECULE:
Beta-ursolic acid is a plant-derived phyto-steroid-like compound that naturally mimics anabolic IGF signaling.STUDY:
Despite breakthrough lab-based research, no human studies on the effects of ursolic acid had been conducted until Korean researchers undertook a study. They used 16 subjects, all of whom had been strength training for at least three years. Seven of the subjects were given a placebo [RT] for eight weeks,
BRINGING A NEW PHARMACEUTICAL PEDIGREE TO THE OLD SUPPLEMENT INDUSTRY /////////
008
Future Pharmaceuticals traces its origins to the Santa Fe Institute for Complex Systems, the birthplace of 'complexity science'—a revolutionary field that unites once-disjointed disciplines such as nanotechnology, biotechnology, AI, and genomics to understand complex systems.
Founded in 1984 by renegade scientists frustrated by the confines of traditional research, we sought to push the boundaries of science by addressing its biggest unanswered questions—a spirit that continues to guide Future Pharmaceuticals today.
AT FUTURE PHARMACEUTICALS,
WE TACKLE THE COMPLEX AND MULTICAUSAL PROBLEM OF HUMAN PERFORMANCE WITH AN EQUALLY MULTIFACETED SOLUTION.
RADICAL TECHNOLOGY. RADICAL BIOPHARMA ///////////
GENOMICS
// Cracking The Genetic Source Code Of Life.
ARTIFICAL INTELLIGENCE
// Simulating complex biological ecosystems.
BIOTECHNOLOGY
// Engineering the biological fabric of life
NANOTECHNOLOGY:
// 100% Bioavailability Direct to Target Cell
ALL MADE POSSIBLE BY A COLLABORATION OF WORLD-LEADING SCIENTISTS.
As an interdisciplinary group, we can leverage a multi-factor approach to tackle the multi-factor problem of aging. Operating at the super-convergence of advanced technologies allows us to study cell metabolism as an integrated, interconnected system rather than isolated parts—something traditional reductionist biology is fundamentally incapable of.
009FOSTERING CULTURE OF DISRUPTIVE SCIENCE
By combining the resources and scientific pedigree of institutional academia with the disruptive mindset and cutting-edge technology of a startup, we foster breakthroughs that push the boundaries of possibility.
Free from the constraints of corporate bureaucracy and rigid scientific ideology, our skunkworks research lab encourages bold innovation, risk-taking experimentation, and unconventional thinking—surpassing the limitations of traditional medical research.
COMBINING OLD
ACADEMIA WITH NEW
TECHNOLOGY FOR TOMMOROW’S PHARMACEUTICALS
LEGENDARY MIT PROFESSOR CLAUD SHANNON /////////// "WE ADMIRE THE SKUNKWORKS MODEL OF BELL LABS. HIRE A LOT OF REALLY TALENTED PEOPLE, INSPIRE THEM WITH AN ASPIRATIONAL GOAL LIKE UNDERSTANDING AGING, PROVIDE THEM WITH RESOURCES AND ACCESS TO ADVANCED TECHNOLOGY, AND GIVE THEM THE FREEDOM TO COLLABORATE ON THINGS THEY ARE PASSIONATE ABOUT...AND INCREDIBLE THINGS CAN HAPPEN."
MIT AND BELL LABS PROFESSOR CLAUDE SHANNON’S QUANTUM BIOLOGY BREAKTHROUGH THAT INVENTED THE FUTURE.
Our work at Future is fundamentally underpinned by Claude Shannon’s revolutionary Information Theory, which redefined all life as a fundamentally information-based phenomenon. With this perspective, DNA becomes a code—the cell’s epigenetic operating system—that can be read and programmed like a computer.
010AT FUTURE, WE’RE BRINGING ADVANCES IN ANTI-AGING SCIENCE DIRECTLY TO HUMANS—AND WE CAN ALREADY SEE THE FUTURE.
A fully-loaded product pipeline in various stages of clinical development, Nobel Prize-winning advisors, partnerships with elite institutions—and much more.
Our current pipeline includes preclinical and clinical trials for muscle, metabolism, cognitive, and aerobic enhancement. Beyond Pro Anabolic, Metabolic, NeuroGenesis, and OxyGen, we are working with our scientific advisors and university partners to identify promising new research and innovative compounds.
As you can see from our clinical trial pipeline outlined below, there’s a lot happening behind the scenes at Future—and a lot to look forward to.
-
HEADLINE CLINICAL TRIAL DATA
50-80% greater endurance
Harvard Medical School : Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging
30% strength gain, 10% mass gain
Elevates IGF by 22.8% and mTOR-ATF4 muscle protein synthesis activity by 1.8 FoldDepartments of Internal Medicine, The University of Iowa, Identification and Small Molecule Inhibition of an Activating Transcription Factor 4 (ATF4)-dependent Pathway to Age-related Skeletal Muscle Weakness and Atrophy*
7% strength gain in 7 daysMaster Myostatin OFF switch inhibition inhibits catabolic muscle loss by 50%
Mexican Escuela Superior de Medicine del Instituto Politecnico Nacional, Effects of (−)-epicatechin on molecular modulators of skeletal muscle growth and differentiation
2KG muscle growth, 19.4% strength
Activating mTOR master ON muscle growth switch by 200% with 120% greater Protein Synthesis
Cologne Sports University Freie Universitaet Berlin , Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans+88% Free Anabolic Testosterone
Safely Activates body to naturally produce more testosterone via sTAR molecular pathway
Texas Tech University, ‘’Effects of apigenin on steroidogenesis and steroidogenic acute regulatory gene expression in mouse Leydig cells
-50% Catabolic estrogen
inhibits aromatase, the enzyme responsible for converting anabolic testosterone into catabolic estradiol, by 70.4% - 80.5%.
Beckman Research Institute in California, Kijima, Ikuko et al. “Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression.
-
COMING SOON 2025
-
Description text goes here
-
Item description
-
Item description